DK3512544T3 - Peptidforbindelser og terapeutiske anvendelser deraf - Google Patents
Peptidforbindelser og terapeutiske anvendelser deraf Download PDFInfo
- Publication number
- DK3512544T3 DK3512544T3 DK17771531.5T DK17771531T DK3512544T3 DK 3512544 T3 DK3512544 T3 DK 3512544T3 DK 17771531 T DK17771531 T DK 17771531T DK 3512544 T3 DK3512544 T3 DK 3512544T3
- Authority
- DK
- Denmark
- Prior art keywords
- therapeutic uses
- peptide compounds
- peptide
- compounds
- therapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/50—Cyclic peptides containing at least one abnormal peptide link
- C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
- C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
- C07K7/62—Polymyxins; Related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1615560.8A GB201615560D0 (en) | 2016-09-13 | 2016-09-13 | Novel compounds and therapeutic uses thereof |
GBGB1707076.4A GB201707076D0 (en) | 2017-05-04 | 2017-05-04 | Novel compounds and therapeutic uses thereof |
PCT/GB2017/052699 WO2018051085A1 (en) | 2016-09-13 | 2017-09-13 | Novel compounds and therapeutic uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3512544T3 true DK3512544T3 (da) | 2021-02-01 |
Family
ID=59923474
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK17771531.5T DK3512544T3 (da) | 2016-09-13 | 2017-09-13 | Peptidforbindelser og terapeutiske anvendelser deraf |
Country Status (14)
Country | Link |
---|---|
US (1) | US11014966B2 (da) |
EP (1) | EP3512544B1 (da) |
JP (2) | JP7185622B2 (da) |
KR (1) | KR102544465B1 (da) |
CN (1) | CN110022896B (da) |
AU (1) | AU2017328896B2 (da) |
BR (1) | BR112019004877A2 (da) |
CA (1) | CA3036405A1 (da) |
DK (1) | DK3512544T3 (da) |
ES (1) | ES2854991T3 (da) |
IL (1) | IL265269B (da) |
MX (1) | MX2019002879A (da) |
WO (1) | WO2018051085A1 (da) |
ZA (1) | ZA201901422B (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201705686D0 (en) * | 2017-04-07 | 2017-05-24 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
GB201804098D0 (en) * | 2018-03-14 | 2018-04-25 | Centauri Therapeutics Ltd | Novel compounds and therapeutic uses thereof |
GB201904534D0 (en) | 2019-04-01 | 2019-05-15 | Centauri Therapeutics Ltd | Novel compounds an therapeutic uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7645743B2 (en) | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
CN1747970A (zh) * | 2003-02-06 | 2006-03-15 | 三肽公司 | 抗原/抗体或配体/受体糖基化的特异性交换剂 |
ATE553113T1 (de) * | 2003-02-28 | 2012-04-15 | Agenus Inc | Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen |
WO2010129666A1 (en) * | 2009-05-05 | 2010-11-11 | Altermune Technologies, Llc | Chemically programmable immunity |
EP2780357A1 (en) * | 2011-11-18 | 2014-09-24 | Novacta Biosystems Limited | Polymyxin derivatives |
JPWO2016104647A1 (ja) | 2014-12-25 | 2017-10-05 | 国立大学法人大阪大学 | 糖鎖結合ワクチン抗原及び糖鎖導入剤 |
GB201517859D0 (en) * | 2015-10-08 | 2015-11-25 | Altermune Ltd | Novel compounds and therapeutic uses thereof |
-
2017
- 2017-09-13 JP JP2019513946A patent/JP7185622B2/ja active Active
- 2017-09-13 WO PCT/GB2017/052699 patent/WO2018051085A1/en unknown
- 2017-09-13 BR BR112019004877A patent/BR112019004877A2/pt unknown
- 2017-09-13 CN CN201780069622.1A patent/CN110022896B/zh active Active
- 2017-09-13 MX MX2019002879A patent/MX2019002879A/es unknown
- 2017-09-13 KR KR1020197010569A patent/KR102544465B1/ko active IP Right Grant
- 2017-09-13 ES ES17771531T patent/ES2854991T3/es active Active
- 2017-09-13 CA CA3036405A patent/CA3036405A1/en active Pending
- 2017-09-13 DK DK17771531.5T patent/DK3512544T3/da active
- 2017-09-13 EP EP17771531.5A patent/EP3512544B1/en active Active
- 2017-09-13 US US16/333,219 patent/US11014966B2/en active Active
- 2017-09-13 AU AU2017328896A patent/AU2017328896B2/en active Active
-
2019
- 2019-03-07 ZA ZA201901422A patent/ZA201901422B/en unknown
- 2019-03-11 IL IL265269A patent/IL265269B/en unknown
-
2022
- 2022-09-09 JP JP2022143727A patent/JP2022184922A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
KR102544465B1 (ko) | 2023-06-19 |
US20190248838A1 (en) | 2019-08-15 |
IL265269B (en) | 2022-04-01 |
WO2018051085A1 (en) | 2018-03-22 |
CA3036405A1 (en) | 2018-03-22 |
IL265269A (en) | 2019-05-30 |
CN110022896A (zh) | 2019-07-16 |
MX2019002879A (es) | 2019-09-18 |
KR20190064592A (ko) | 2019-06-10 |
EP3512544A1 (en) | 2019-07-24 |
ES2854991T3 (es) | 2021-09-23 |
AU2017328896B2 (en) | 2024-07-25 |
ZA201901422B (en) | 2020-11-25 |
JP2022184922A (ja) | 2022-12-13 |
CN110022896B (zh) | 2023-12-19 |
BR112019004877A2 (pt) | 2019-06-11 |
AU2017328896A1 (en) | 2019-04-04 |
EP3512544B1 (en) | 2020-10-28 |
JP7185622B2 (ja) | 2022-12-07 |
JP2019526614A (ja) | 2019-09-19 |
US11014966B2 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3463465T3 (da) | Exosomer omfattende terapeutiske polypeptider | |
DK3283106T3 (da) | Terapeutiske antistoffer og anvendelser deraf | |
DK3448386T3 (da) | Isoquinolin-3-ylcarboxamider og fremstilling og anvendelse deraf | |
DK3365368T3 (da) | Tgfbeta1-bindende immunoglobuliner og anvendelse deraf | |
DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
DK3268470T3 (da) | Transposasepolypeptider og anvendelser deraf | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
DK3723783T3 (da) | Mitokondrie-målrettede peptider | |
DK3498292T3 (da) | Uspa2-proteinkonstruktioner og anvendelser deraf | |
DK3102200T3 (da) | Terapeutisk forbindelse og sammensætning | |
DK3290441T3 (da) | Rgma-bindingsprotein og anvendelse deraf | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3408265T3 (da) | Terapeutiske forbindelser | |
DK3615502T3 (da) | Terapeutiske forbindelser og fremgangsmåder | |
DK3560925T3 (da) | Hidtil ukendt forbindelse og farmaceutisk acceptabelt salt deraf | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
ZA201902689B (en) | Therapeutic protein | |
DK3194583T3 (da) | Ikke-fucosyleret protein og fremgangsmåder dermed | |
DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf | |
DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
DK3512544T3 (da) | Peptidforbindelser og terapeutiske anvendelser deraf |